Feb 18 (Reuters) - Chemours Co CC.N:
CHEMOURS: OUTLOOK FY ADJUSTED EBITDA BETWEEN $825 MILLION AND $975 MILLION
CHEMOURS: OUTLOOK FY CAPITAL EXPENDITURES BETWEEN $250 MILLION TO $300 MILLION
CHEMOURS: OUTLOOK Q1 CONSOLIDATED NET SALES TO BE FLAT TO SLIGHTLY DOWN SEQUENTIALLY
CHEMOURS: QTRLY NET SALES OF $1.4 BILLION
CHEMOURS: QTRLY ADJUSTED EPS $0.11
CHEMOURS: IN 2024, FULLY REMEDIATED ALL FOUR MATERIAL WEAKNESSES IN INTERNAL CONTROL PREVIOUSLY IDENTIFIED IN THE 2023 FORM 10-K
Q4 EARNINGS PER SHARE VIEW $0.12, REVENUE VIEW $1.36 BILLION -- LSEG IBES DATA
Q1 REVENUE VIEW $1.41 BILLION -- LSEG IBES DATA
Source text: ID:nBwb2qq3ha
Further company coverage: CC.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.